Reviva Pharmaceuticals (RVPH) News Today $1.57 -0.06 (-3.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.53 -0.04 (-2.48%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Unusually active option classes on open February 12thFebruary 12, 2025 | markets.businessinsider.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of "Buy" from AnalystsReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a sFebruary 5, 2025 | marketbeat.comReviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comReviva to Participate in the 2025 BIO CEO & Investor ConferenceJanuary 30, 2025 | globenewswire.comShort Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Decreases By 35.9%Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 5,640,000 shares, a decrease of 35.9% from the December 31st total of 8,800,000 shares. Based on an average daily volume of 2,360,000 shares, the days-to-cover ratio is currently 2.4 days.January 29, 2025 | marketbeat.comHC Wainwright Has Positive Outlook of RVPH FY2024 EarningsReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Reviva Pharmaceuticals in a report issued on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the cJanuary 24, 2025 | marketbeat.comReviva Pharmaceuticals price target lowered to $11 from $14 at H.C. WainwrightJanuary 22, 2025 | markets.businessinsider.comReviva Pharmaceuticals (NASDAQ:RVPH) Given New $11.00 Price Target at HC WainwrightHC Wainwright lowered their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a "buy" rating for the company in a research note on Wednesday.January 22, 2025 | marketbeat.comReviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday.January 22, 2025 | marketbeat.comReviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading on Tuesday. Investors acquired 13,196 call options on the stock. This is an increase of 374% compared to the typical volume of 2,782 call options.January 22, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 13,196 call options on the company. This is an increase of approximately 374% compared to the average daily volume of 2,782 call options.January 21, 2025 | marketbeat.comReviva Pharmaceuticals' (RVPH) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday.January 21, 2025 | marketbeat.comShort Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Drops By 35.9%Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 5,640,000 shares, a drop of 35.9% from the December 15th total of 8,800,000 shares. Based on an average trading volume of 2,360,000 shares, the days-to-cover ratio is currently 2.4 days.January 14, 2025 | marketbeat.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of "Buy" by AnalystsShares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) have received a consensus recommendation of "Buy" from the five brokerages that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation and one has given aJanuary 11, 2025 | marketbeat.comReviva Pharmaceuticals (NASDAQ:RVPH) Upgraded by Roth Capital to "Strong-Buy" RatingRoth Capital upgraded shares of Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Friday.January 11, 2025 | marketbeat.comReviva Pharmaceuticals upgraded to Buy from Hold at MaximJanuary 10, 2025 | markets.businessinsider.comReviva Pharmaceuticals (NASDAQ:RVPH) Upgraded to Buy at Maxim GroupMaxim Group upgraded Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price objective on the stock in a research report on Friday.January 10, 2025 | marketbeat.comReviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated by Analysts at Roth MkmRoth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $7.00 price objective on the stock.January 10, 2025 | marketbeat.comReviva to Participate in the Lytham Partners 2025 Investor Healthcare SummitJanuary 7, 2025 | globenewswire.comReviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 4,052 call options on the stock. This represents an increase of approximately 103% compared to the typical daily volume of 1,999 call options.January 2, 2025 | marketbeat.comFY2024 Earnings Forecast for RVPH Issued By Zacks Small CapReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Stock analysts at Zacks Small Cap upped their FY2024 earnings per share (EPS) estimates for shares of Reviva Pharmaceuticals in a report released on Monday, December 23rd. Zacks Small Cap analyst J. Vandermosten now anticipates tDecember 25, 2024 | marketbeat.comRVPH: Preliminary OLE ReadoutDecember 23, 2024 | msn.comReviva Pharmaceuticals Strengthens Financial Position with OfferingDecember 18, 2024 | markets.businessinsider.comReviva Pharmaceuticals 12M share Spot Secondary priced at $1.50December 17, 2024 | markets.businessinsider.comReviva Announces Proposed Public OfferingDecember 16, 2024 | globenewswire.comReviva Announces Prel. Topline OLE Data Of Phase 3 RECOVER Study Of Brilaroxazine In SchizophreniaDecember 16, 2024 | markets.businessinsider.comReviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is LowDecember 11, 2024 | seekingalpha.comRVPH: Year-End OLE UpdateNovember 19, 2024 | msn.comReviva Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comReviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024November 6, 2024 | globenewswire.comReviva to Participate in the UBS Global Healthcare ConferenceOctober 31, 2024 | globenewswire.comReviva to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | globenewswire.comReviva to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comReviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor ConferenceSeptember 26, 2024 | markets.businessinsider.comReviva Pharmaceuticals Holdings, Inc. (RVPHW)September 12, 2024 | ca.finance.yahoo.comReviva Pharmaceuticals Holdings (RVPH) Earnings Dates & ReportsSeptember 12, 2024 | investing.comReviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | finanznachrichten.deReviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | markets.businessinsider.comRVPH Jan 2026 5.000 callSeptember 8, 2024 | ca.finance.yahoo.comReviva to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comRVPH: August OLE UpdateAugust 27, 2024 | msn.comExplainer-Big Tech wants AI to be regulated. Why do they oppose a California AI bill?August 21, 2024 | msn.comReviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq RulesAugust 21, 2024 | globenewswire.comMaxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH)August 17, 2024 | msn.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024August 14, 2024 | investorplace.comReviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary FibrosisAugust 6, 2024 | finance.yahoo.comReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary HypertensionJuly 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 30, 2024 | prnewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.com Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPH Media Mentions By Week RVPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼0.000.60▲Average Medical News Sentiment RVPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼01▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LFVN News VYGR News DSGN News FDMT News LFCR News CCCC News CRDF News SLRN News LRMR News OCGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
